Maxcyte Inc (MXCT) Stock Price, Quote & News

Company Profile

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications;...

Industry: Medical Devices

Sector: Healthcare

Phone: 301 944 1700

Website: www.maxcyte.com

Address:

9713 Key West Avenue, Suite 400, Rockville, United States

BeefStewart Nov. 15 at 4:44 AM

$MXCT I still believe that this remains a solid long term investment. The fact that it did not see a sustained selloff despite the quarter being difficult (as expected) suggests to me that investors are confident in the company's ability to succeed long-term. Also, seemingly no negative reaction to the CFO leaving and the CFO made it clear that he is not rushing out the door.

0 · Reply

BeefStewart Nov. 14 at 6:30 PM

$MXCT 🙏🙏🙏🙏🙏

0 · Reply

BeefStewart Nov. 13 at 6:38 PM

$MXCT Cost cutting measures expected to save 17-19 million annually.

0 · Reply

BeefStewart Nov. 13 at 6:36 PM

$MXCT held up well most of the morning, only to catch up with the sell-off in the afternoon... The volume is still quite low on the drop, though.

0 · Reply

DARKP00L Nov. 12 at 9:23 PM

$MXCT 16:17 on Nov. 12 2025 MaxCyte CFO Douglas Swirsky To Transition From Role In H1 2026 #tradeideas

0 · Reply

DARKP00L Nov. 12 at 9:22 PM

$MXCT 16:10 on Nov. 12 2025 MaxCyte Affirms FY2025 Sales Guidance of $29.261M-$32.512M vs $36.402M Est #tradeideas

0 · Reply

BeefStewart Nov. 12 at 8:56 PM

$MXCT Very low volume... I don't know if I've ever seen it this low. Hopefully great news is coming soon!💚🙏

0 · Reply

BeefStewart Nov. 11 at 8:43 PM

$MXCT did anyone listen to the Stifel 2025 Healthcare Conference Fireside Chat this morning?🥹

1 · Reply

BeefStewart Nov. 11 at 6:45 PM

$MXCT🥹

0 · Reply

BeefStewart Nov. 11 at 3:34 PM

$MXCT I wish we could see some sustained buying today...

0 · Reply

MaxCyte, Inc. (MXCT) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 4:08 PM EST - 2 days ago

MaxCyte Announces Planned CFO Transition in 2026

Nov 12, 2025, 4:05 PM EST - 2 days ago

MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

Nov 5, 2025, 8:05 AM EST - 9 days ago

MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

Oct 8, 2025, 8:05 AM EDT - 5 weeks ago

MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025

Oct 6, 2025, 8:05 AM EDT - 5 weeks ago

MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors

Sep 22, 2025, 4:30 PM EDT - 7 weeks ago

MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability

Aug 7, 2025, 3:45 AM EDT - 3 months ago

MaxCyte, Inc. (MXCT) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 8:05 AM EDT - 3 months ago

MaxCyte Signs Platform License Agreement with Adicet Bio

Jul 31, 2025, 8:05 AM EDT - 3 months ago

MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline

Jul 9, 2025, 8:05 AM EDT - 4 months ago

MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 1, 2025, 1:00 AM EDT - 4 months ago

PHC Announces Exclusive Distribution of MaxCyte® ExPERT™ Platform in Japan

Jun 11, 2025, 2:00 AM EDT - 5 months ago

MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies

May 10, 2025, 11:57 PM EDT - 6 months ago

MaxCyte, Inc. (MXCT) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:05 PM EDT - 6 months ago

MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance

Apr 10, 2025, 2:00 AM EDT - 7 months ago

MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025

Mar 15, 2025, 8:30 AM EDT - 8 months ago

MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market, Very Low Share Price

Mar 11, 2025, 7:52 PM EDT - 8 months ago

MaxCyte, Inc. (MXCT) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 4:05 PM EDT - 8 months ago

MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance

Feb 12, 2025, 2:00 AM EST - 9 months ago

MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs

Feb 7, 2025, 2:00 AM EST - 10 months ago

MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference

Jan 30, 2025, 10:36 AM EST - 10 months ago

Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT)

Jan 30, 2025, 2:00 AM EST - 10 months ago

MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments

Jan 13, 2025, 3:05 AM EST - 10 months ago

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

Dec 23, 2024, 2:00 AM EST - 11 months ago

MaxCyte Announces Retirement of Board Member Art Mandell

Dec 9, 2024, 2:00 AM EST - 1 year ago

MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance

Nov 13, 2024, 8:05 AM EST - 1 year ago

MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics

Nov 6, 2024, 10:01 PM EST - 1 year ago

MaxCyte, Inc. (MXCT) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:05 PM EST - 1 year ago

MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance

Oct 31, 2024, 8:05 AM EDT - 1 year ago

MaxCyte to Participate in Two Upcoming Investor Conferences

Oct 15, 2024, 8:05 AM EDT - 1 year ago

MaxCyte Appoints Cynthia Collins to its Board of Directors

Oct 11, 2024, 8:05 AM EDT - 1 year ago

MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024

Oct 10, 2024, 8:05 AM EDT - 1 year ago

MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer

Oct 4, 2024, 5:19 PM EDT - 1 year ago

Maxcyte: Reaching Financial Inflection With CASGEVY Ramp Up

Sep 16, 2024, 2:00 AM EDT - 1 year ago

MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases

Sep 5, 2024, 4:05 PM EDT - 1 year ago

MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference

Aug 7, 2024, 12:09 AM EDT - 1 year ago

MaxCyte, Inc. (MXCT) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:05 PM EDT - 1 year ago

MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance

Jul 9, 2024, 4:05 PM EDT - 1 year ago

MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024

May 29, 2024, 8:05 AM EDT - 1 year ago

MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference

May 22, 2024, 8:05 AM EDT - 1 year ago

MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development

May 11, 2024, 8:35 AM EDT - 1 year ago

MaxCyte, Inc. (MXCT) Q1 2024 Earnings Call Transcript

May 7, 2024, 4:05 PM EDT - 1 year ago

MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance

Apr 10, 2024, 8:05 AM EDT - 1 year ago

MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024

Apr 2, 2024, 8:05 AM EDT - 1 year ago

MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)

Mar 12, 2024, 10:40 PM EDT - 1 year ago

MaxCyte, Inc. (MXCT) Q4 2023 Earnings Call Transcript

Mar 12, 2024, 4:05 PM EDT - 1 year ago

MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance

Mar 4, 2024, 4:05 PM EST - 1 year ago

MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results

Feb 9, 2024, 8:05 AM EST - 1 year ago

MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences

Jan 30, 2024, 8:05 AM EST - 1 year ago

MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen's Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers

BeefStewart Nov. 15 at 4:44 AM

0 · Reply

BeefStewart Nov. 14 at 6:30 PM

$MXCT 🙏🙏🙏🙏🙏

0 · Reply

BeefStewart Nov. 13 at 6:38 PM

$MXCT Cost cutting measures expected to save 17-19 million annually.

0 · Reply

BeefStewart Nov. 13 at 6:36 PM

$MXCT held up well most of the morning, only to catch up with the sell-off in the afternoon... The volume is still quite low on the drop, though.

0 · Reply

DARKP00L Nov. 12 at 9:23 PM

$MXCT 16:17 on Nov. 12 2025 MaxCyte CFO Douglas Swirsky To Transition From Role In H1 2026 #tradeideas

0 · Reply

DARKP00L Nov. 12 at 9:22 PM

$MXCT 16:10 on Nov. 12 2025 MaxCyte Affirms FY2025 Sales Guidance of $29.261M-$32.512M vs $36.402M Est #tradeideas

0 · Reply

BeefStewart Nov. 12 at 8:56 PM

$MXCT Very low volume... I don't know if I've ever seen it this low. Hopefully great news is coming soon!💚🙏

0 · Reply

BeefStewart Nov. 11 at 8:43 PM

$MXCT did anyone listen to the Stifel 2025 Healthcare Conference Fireside Chat this morning?🥹

1 · Reply

BeefStewart Nov. 11 at 6:45 PM

$MXCT🥹

0 · Reply

BeefStewart Nov. 11 at 3:34 PM

$MXCT I wish we could see some sustained buying today...

0 · Reply

BeefStewart Nov. 11 at 3:32 PM

$MXCT

0 · Reply

BeefStewart Nov. 11 at 3:30 PM

$MXCT🥹

0 · Reply

rooneyray Nov. 10 at 8:45 PM

$MXCT Here's the chart. Fundamentals aside, I can tell you that MA momentum-based TA traders have exited and it's no longer considered "technically bullish". Nonetheless, it's still holding up near the support, which TA value betters would usually enter. At the end of the day, all of this is probably meaningless since Wednesday will probably be the trendsetter.

1 · Reply

BeefStewart Nov. 10 at 7:50 PM

$MXCT to recap: -large cash position (152M-155M by end of year) -no debt -opex reduction plan initiated (34% headcount reduction underway) -32 SPL partnerships in place with Casgevy already commercialized and paying modest royalties -Significant insider buying in August -anticipated growth in 2026 via Asia-Pacific market Trading as though the biz is worthless despite having a whole bunch going on, and opportunity for their core biz to grow.

0 · Reply

BeefStewart Nov. 7 at 6:18 PM

$MXCT from the preliminary ER release: This is good news, in my opinion.

0 · Reply

BeefStewart Nov. 7 at 2:36 PM

$MXCT if anything, I would think that the chaos with $NTLA would support ex vivo platforms such as what MXCT uses...

1 · Reply

BeefStewart Nov. 7 at 1:06 PM

From ChatGPT: $MXCT Buyout Thesis (Final + Precise): MaxCyte enables ex vivo cell engineering across ~30 SPL partners and 50+ partnered therapy programs — including Casgevy and Caribou’s allogeneic CAR-T. Clean balance sheet (no debt), ~$155M YE cash, recurring consumables, and milestone/royalty optionality. At current valuation, EV ≈ zero. This is the kind of platform Thermo Fisher / Danaher / Sartorius acquires to secure control of cell therapy manufacturing infrastructure.

0 · Reply

BeefStewart Nov. 6 at 10:58 PM

$MXCT I really can't reliably predict anything. I can only say that I believe this is fundamentally undervalued. 152M-155M in cash by year end 34% opex reduction beginning already growth expected next year insiders loading up I'm not convinced it is only worth 1.47 a share. I've been wrong before, but I don't think I am wrong here. I guess we will find out in time...

0 · Reply

BeefStewart Nov. 6 at 10:03 PM

$MXCT They expect to end the year with 152M to 155M in cash. They delayed earnings because of favorable updates from clients: "This impairment testing takes into consideration certain recent developments including favorable announcements from SPL partners and does not impact financial results reported for prior quarters." The drop today makes no sense to me. $NTLA dropping after hours. I hope people do not mistakenly conlfate mxct with ntla.

0 · Reply

CH_Expat Nov. 6 at 9:27 PM

$MXCT Might open a position tomorrow when red.

1 · Reply

BeefStewart Nov. 6 at 9:08 PM

$MXCT Weird day. Low volume shake out, in my opinion. Nothing has fundamentally changed. Everything looks good. The stock closed green yesterday at 1.67 after the preliminary Q3 results...

0 · Reply

BeefStewart Nov. 6 at 6:27 PM

$MXCT looks like some buying has resumed

0 · Reply

Market Cap	160.98M
Revenue (ttm)	38.63M
Net Income (ttm)	-41.06M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-106.29%
Debt to Equity Ratio	0.00

Volume	2,844,100
Avg Vol	705,456
Day's Range	N/A - N/A
Shares Out	106.61M
Stochastic %K	62%
Beta	1.23
Analysts	Strong Sell
Price Target	$7.00